Well before COVID-19 entered the picture, however, many scientists were growing frustrated with the rituals and delays associated with publication in peer-reviewed journals, as well as the high cost of subscriptions, and the open science movement sprang from that discontent.
Hutch evolutionary biologist Dr. Jesse Bloom, who like both Malik and Biggins is also a Howard Hughes Medical Institute Investigator, was drawn to open science in 2014 because he saw it as a way to devote more time to the lab bench.
“Peer review can be very slow, and it is nice to have a paper done, out there where other people can see it, and feel like you can move on to the next thing,” he said. “I still think we should have peer review as a quality control, but most people are also aware of their reputations as scientists, so they are careful what they post.”
Bloom has also taken to Twitter, as many of his colleagues have done, to expand the network of people who are aware of his recent COVID-19 research. He recently used a Twitter thread to explain how work on re-infection by influenza and measles puts into context recent reports of re-infection by SARS-CoV-2. His thread offered a reassuring conclusion that re-infection with SARS-CoV-2 is not concerning unless it turns out to be a frequent occurrence.
Bloom’s lab posted its own bioRxiv preprint in June describing their technique of “deep mutational scanning,” which they used to test the effects of every conceivable mutation of a key structure on the spike of the coronavirus, which it uses to bind with the ACE2 receptor found on the surface of many human cells — including those deep in the lung. The same research was subsequently peer-reviewed and published on Aug. 11 in Cell, which, as most top scientific journals have been doing with COVID-19 papers, made the article available on open access — free to anyone.
A rough cut of the future of science
That sequence of discussing work publicly via social media, publishing research in preprints for crowd-sourced discussion and peer review, and then publication in open access, peer-reviewed, high-impact journals may be a rough cut of how science of all kinds is carried out in the future.
Hutch physician-researcher Dr. Joshua Hill and his colleagues recently participated with University of Washington researchers in a study of whether a drug that dampens immune responses, tocilizumab, might tone down the extreme immune reaction known as a cytokine storm that is responsible for the deaths of many COVID-19 patients. Their study found that the costly drug did not improve patient outcomes.
As the results became apparent, he and co-principal investigator Dr. Guang-Shing Cheng discussed posting the article on a preprint server, but thought it better to wait for publication in a peer-reviewed journal. Shortly after they submitted it for publication, editors of the peer-reviewed journal reached out to them to suggest they post it first on a preprint server and to share the findings with the World Health Organization. On Aug. 11, the team posted their work on medRxiv, and their manuscript in a peer-reviewed journal is still under review.
But in the COVID-19 era, traditional routes from the lab bench to the bedside are changing.
On Aug. 27, the National Institutes of Health COVID-19 Treatment Guidelines Panel, which previously was neutral on use of tocilizumab, switched to recommend against it for treatment of the disease. It cited not a paper, but a July 28 press release from the drug’s maker, Genentech, which announced that the drug had not met its goals in a large clinical trial. Results of that trial, which have yet to be published in a peer-reviewed journal, were posted on medRxiv on Sept. 1, a week after the NIH decision.
In medical research labs around the country, scientists are participating in a dramatic change in how their work is carried out and how the results of their experiments are revealed. This movement toward open science predates COVID-19, but the mortal and economic threat of this virus has accelerated that trend among those most intimately engaged in the scientific struggle to stop it.
Whether that trend spills over to other realms of science in the U.S. or abroad remains to be seen, but should that happen, chalk it up to another way COVID-19 has changed the world.